title: [The therapy of the postextraction syndrome with Taurolin. A controlled clinical study].
abstract: In a controlled clinical study with a total of 200 patients the broad spectrum agent and antitoxin taurolidine (Taurolin) was clearly superior to conventional medication with the broad spectrum antibiotic chlortetracycline (Aureomycin) when applied topically to treat the postextraction syndrome. Thus, the mean duration of therapy (primary target criterion) with Taurolin (group A) was 5.6 days compared to 8.2 days with the standard therapy (group B). In statistical terms this difference was highly significant (p < 0.0001). Compared with the conventionally treated patient group, the clinical control parameters such as pain, swelling, secretion, tenderness to pressure and remission (secondary target criteria) in the Taurolin group exhibited not only a markedly more rapid normalisation of the score-data during the initial phase, but also an appreciably shorter interval until the patients were symptom-free. Age, gender, localisation of the lesion or facultative systemic antibiotic or analgetic administration had no demonstrable effect on the course of the treatment, although the patients in the reference group required concomitant medication with antibiotics (p = 0.007) and analgetics (p = 0.01) considerably more often than those in the Taurolin group.
authors: Klinik und Poliklinik für Kieferchirurgie, Universität München.
authors: M
authors: M
authors: Zimmermann
authors: G H
authors: GH
authors: Nentwig
mesh_terms: D000328:Adult; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D004368:Dry Socket / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013577:Syndrome; D013654:Taurine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013829:Thiadiazines / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000891:Anti-Infective Agents, Local; D013829:Thiadiazines; D013654:Taurine; C012566:taurolidine
vernacular_title: Die Therapie des Postextraktionssyndroms mit Taurolin. Eine kontrollierte klinische Studie.